CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 31-33

  Brandhorst, G ^a   Weigand, S ^a   Eberle, C ^a   Raddatz, D ^a   Karaus, M ^b   Oellerich, M ^a   Walson, P D ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Sleep Laboratory   (Germany)

Author keywords

Biomarkers; Cylex; ImmuKnow; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; ALBUMIN; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DRUG USE; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MONITORING; PERCEPTION; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SIMPLE CLINICAL COLITIS ACTIVITY INDEX; STRUCTURED QUESTIONNAIRE; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; ALBUMINS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84875577536     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.016     Document Type: Article

References (24)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
2. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
3. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
4. Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., Meyer zum Buschenfelde K.H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995, 102:448-455.
5. Mow W.S., Vasiliauskas E.A., Lin Y.C., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-424.
6. Baumgart D.C. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int 2009, 106:123-133.
7. Matricon J., Barnich N., Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself 2010, 1:299-309.
8. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008, 8:458-466.
9. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
10. Barrett J.C., Hansoul S., Nicolae D.L., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
11. Oellerich M., Barten M.J., Armstrong V.W. Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit 2006, 28:35-38.
12. Wieland E., Olbricht C.J., Susal C., et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010, 32:560-572.
13. Brandhorst G., Oellerich M., Brunet M., Kowalski R., Vinks A., Wallemacq P. Individually tailored immunosuppression: is there a role for biomarkers?. Clin Chem 2011, 57:376-381.
14. Wieland E., Shipkova M., Oellerich M. Biomarkers in transplantation medicine: guide to the next level in immunosuppressive therapy. Clinica Chemica Acta 2012, 413:1309.
15. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
16. Thai N.L., Blisard D., Tom K., et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 2006, 82:1649-1652.
17. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
18. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
19. Walmsley R.S., Ayres R.C., Pounder R.E., Allan R.N. A simple clinical colitis activity index. Gut 1998, 43:29-32.
20. Stange E.F., Travis S.P., Vermeire S., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006, 55(Suppl. 1):i1-i15. [Asas].
21. Batal I., Zeevi A., Heider A., et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 2008, 129:587-591.
22. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003, 17:77-88.
23. Sostegni R., Daperno M., Scaglione N., Lavagna A., Rocca R., Pera R. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003, 17(Suppl. 2):11-17.
24. Cooney R.M., Warren B.F., Altman D.G., Abreu M.T., Travis S.P.L. Outcome measurement in clinical trials for ulcerative colitis: towards standardization. Trials 2007, 8:17. [available at http://www.trialsjournalcom/content/8/1/17].